Introduction
The zebrafish (Danio rerio) is a popular tropical pet fish that has been exploited for many years as a genetically tractable model of developmental biology [1] .
Since the egg is fertilized after laying, zebrafish embryos develop externally to the mother, making them accessible for injection with genetic constructs or exposure to chemical treatment from the earliest stages. The near transparency of early embryos allows observation of organ development without the need for invasive manipulation. Tissue specific transgenics that express fluorescent reporters in the heart [2], endothelium [3, 4] or blood [5] have allowed cardiovascular researchers to visualize cardiovascular development in a manner impossible using mammalian models. More recently, the zebrafish has been applied to drug discovery in attempts to identify small molecules with potential therapeutic effects. The first zebrafish based small molecule screen was published in 2000 [6] , since when the results of at least fifty subsequent screens have been described. As with any model system, the zebrafish possesses advantages and disadvantages that must be appreciated when considering a zebrafish based small molecule screen, and we outline these below.
Advantages of zebrafish screens
The zebrafish boasts many advantages for drug screening. Fertile females lay several hundred eggs per week, which simply require incubation in medium to allow development until the onset of feeding at around 5 days post fertilization (dpf). Embryonic development proceeds rapidly; by 24 hours post fertilization (hpf) a recognizable vertebrate body plan is in place, with a primitive vasculature and a two chambered beating heart [7] . Embryos can be automatically dispensed into 96 well plates (generally 3-5 embryos/well) and survive in low volumes of liquid (100l). Robotic platforms allow rapid application of precise concentrations of small molecule libraries to the medium [8] . These generic features are common to almost all zebrafish-based screens, varying only in the developmental stage of embryo used, the libraries tested, and the zebrafish strain used. These may be transgenics, expressing a tissue specific fluorescent reporter in an organ of interest, mutants with a phenotype the screen aims to rescue or influence, or wildtype embryos, depending on the drug effect being sought. If modulation of expression of a known gene is the effect sought, whole mount in situ hybridization can be performed in an automated manner to assess expression of the target gene in hundreds of embryos in parallel. Figure 1 shows a typical workflow for a zebrafish-based screen. Once a possible hit is identified, rapid rescreening in different doses allows assessment of the drug effect in a more rigorous manner.
Disadvantages of zebrafish screens
Each screen needs a specific assay and the nature of this is critical to the screen s ability to identify true hits without an unacceptable number of false positives and false negatives. A good screen needs a reproducible, rapidly measurable endpoint with minimal variability, and ideally will include positive and negative controls that allow assessment of technical reliability. These considerations limit screens for physiological parameters such as blood flow that are highly variable in early embryos. Although the nature of the screen to some extent determines the throughput, in general at most only a few thousand molecules are tested per screen. This limitation means that most studies use libraries of molecules known to have some bioactive properties, rather than a truly unbiased screen as can be applied to in vitro screening efforts. Once a hit is identified in a zebrafish screen, its mechanism of action is not known, and this can cause difficulty in lead optimization and prediction of other, potentially harmful effects. Most screens test only a single concentration and this, coupled with unpredictable drug penetration, is likely to lead to a significant false negative rate. Although vascular delivery of drugs is possible via microinjection, this is technically challenging and unlikely to be scalable to a level that allows high throughput screening. Although the zebrafish and mammalian genomes are similar, levels of protein homology are generally low, and genome duplication in the fish has led to multiple zebrafish homologues of many human genes [9] . These features raise the possibility that a drug with effect in zebrafish may have no effect on the human homologue due to protein dissimilarity, while a drug that targets a human protein may have no effect on a duplicated zebrafish gene product due to duplication. It remains to be seen to what extent these disadvantages limit the ability of zebrafish -based drug discovery to identify therapeutic compounds for human use.
Screening for drugs with novel cardiovascular effects in zebrafish
Below, we summarize some recent screens that illustrate features of screen design and that have identified promising lead compounds; these are also summarized in Table 1 .
A zebrafish screen to identify anti-arrhythmics
Long QT syndrome (LQTS) in humans predisposes to lethal cardiac arrhythmias 
Zebrafish screens to identify drugs for hyperlipidemia
To identify compounds that inhibit dietary absorption of lipid, zebrafish embryos were fed the fluorescent phospholipid reporter PED-6, which is normally taken up and can be visualized in the gall bladder [13] . The ability of 3840 compounds to prevent this uptake was tested in 5dpf embryos exposed to test compounds prior to feeding. Embryos were examined by fluorescent stereomicroscopy for quantification of gall bladder fluorescence, and compounds that reduced this were considered as primary hits. This screen suffered from a significant false positive rate (1.1%) but was able to identify a number of compounds (whose identities were not revealed) that reliably prevented lipid uptake in rescreening and secondary screens.
Zebrafish screens to identify drugs that modulate angiogenesis
The earliest cardiovascular drug screens in zebrafish sought to identify agents that influence angiogenesis [14] , and this remains the most frequent assay in more recent screens. The availability of endothelial specific transgenics, and the stereotypical and easily observed vascular development in zebrafish has made screening for such molecules particularly successful. Although early screens aimed to identify pan-angiogenesis inhibitors, later studies often aim to find drugs that preferentially affect specific vascular beds (see below).
Xyloketals are natural compounds isolated from an endophytic fungus Xylaria sp.
from the South China Sea [15] with vasorelaxant and angiogenic activities [16, 17] . Xu et al. synthesised 21 novel xyloketal derivatives and tested their effect on angiogenesis in Fli1:GFP transgenic zebrafish that express GFP in the endothelium [17] . When the effect on the subintestinal vein was examined, several of these compounds induced increased branching of this vascular plexus, suggesting that they may promote angiogenesis.
Arterial and venous angiogenesis are differentially regulated during embryogenesis. A recent screen aimed to identify compounds that selectively regulate these two processes [18] . The formation of the caudal vein plexus (CVP) in Fli1:GFP transgenics was used as a model for venous angiogenesis and the formation of primary intersegmental vessels (ISV) was used as the readout for arterial angiogenesis. From 469 compounds, the investigators found that aplexone preferentially suppresses venous angiogenesis while having no effect on primary ISV formation. Aplexone was found to exert its effects via the HMGCoA pathway as evidenced by increased expression of several enzymes of this pathway and decreased cholesterol levels in aplexone-treated embryos. As a result of this, venous ECs exhibit defective posttranslational protein modification geranylgeranylation when treated with aplexone [19, 20] .
In keeping with the observation that some agents are able to disrupt angiogenesis in specific parts of the vasculature while having little effect on others, another group attempted to discover drugs that alter development of the embryonic zebrafish retinal vasculature while sparing angiogenesis elsewhere [21] . From 2000 molecules tested, five reproducibly caused specific changes in retinal vasculature; enalapril maleate, zearalenone, pyrogallin, albendazole and mebendazole.
Supporting the important role of the HMG-CoA pathway in angiogenesis, a separate screen for small molecules that prevents ISV angiogenesis identified a number of HMG-CoA inhibitors (statins) as anti-angiogenic, leading to the authors suggestion that these agents may be able to reduce tumour angiogenesis as an adjuvant to cancer therapy [22] . This is intriguing, given the epidemiological evidence suggesting that statins when taken for prevention of cardiovascular disease may confer some protection from cancer, although a definite link remains unproven [23] .
A recent small screen of eleven compounds known to influence angiogenesis in other systems (recombinant vascular endothelial growth factor (VEGF), Tumour necrosis factor, Adalimumab, Infliximab, Bevacizumab, Oncostatin, Interleukin Nacyselyn and LY also used retinal angiogenesis as its primary assay [24] . Although the selective PI3 Kinase inhibitor LY294002 was shown to inhibit retinal angiogenesis in a dose-dependent manner with no effect on trunk vasculature, the other agents tested had no effect. Although this may seem surprising given the clear role of VEGF in angiogenesis, and the clear reduction in embryonic vascular development seen with VEGF knockdown or small molecule inhibition [25, 26] , peptides such as monoclonal antibodies or growth factors are unable to penetrate the embryo sufficiently to influence vascular development, and as such the zebrafish is unsuited for screening the effects of such molecules.
Zebrafish screens are particularly well suited to assessment of natural products, which contain a diverse and poorly characterized combination of potentially bioactive molecules. In a screen of over 80 East African plant derived natural produces, extracts from Oxygonum sinuatum and Plectranthus barbatus were identified to have anti-angiogenic effect on ISV formation [27] . Once such an effect is detected, fractionation is required to identify which constituent is responsible for the biological effect. expression of blood and vascular markers [30] .
Zebrafish screens to identify drugs that modulate cardiac development

Conclusion
The slowing pace of new drug discovery has been well publicized [31] , and remains in need of a solution. Until a drug that has been discovered in a zebrafish screen has been shown to possess clinical utility, the potential of zebrafish based screens to identify novel drugs remains unproven. Even if zebrafish screens are able to identify therapeutic moieties, given the relative infancy of this approach it is unrealistic to expect translation to clinical application for at least five years.
Nevertheless, even without such a breakthrough, the screens so far conducted have allowed novel insights into disease related mechanisms and pathways. The increasing rate of publication of zebrafish-based screens suggests a growing acceptance of the technology and increasing momentum for its utilization in drug discovery efforts.
Figure 1
Generic workflow for small molecule screen in zebrafish showing the major steps involved from mating the adult zebrafish and collecting the embryos, followed by distribution of the embryos into 96 well plates and the addition of libraries of small molecules to screen. The end assay varies according to the effect sought, but frequently examines vascular development using transgenic embryos, or specific vascular gene expression assessed by in situ hybridization. 
